CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Aminolevulinic Acid (ALA) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02281136
NCT02281136Phase 2Completed
CompareCT.gov

A Pharmacokinetic Study of Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% Under Maximal Use Conditions

DUSA Pharmaceuticals, Inc.·interventional·Posted Nov 3, 2014·Updated Jan 13, 2017

In Brief

A Phase 2 clinical trial evaluating Aminolevulinic Acid (ALA) and BLU-U for Keratosis, Actinic. Completed, enrolled 29 participants across 3 sites.

Detailed Summary

The purpose of this study is to evaluate the potential for systemic exposure of aminolevulinic acid (ALA) when applied topically under occlusion, in a maximal use setting in patients with multiple actinic keratoses (AK) involving the upper extremities.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKeratosis, Actinic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 3, 2014
Enrollment StartDec 1, 2014
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 11.7 years ago

Interventions

Aminolevulinic Acid (ALA)drug

20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

BLU-Udevice

10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2